US equities |
TSLA $394.26 ▲+5.92% MU $889.40 ▲+1.35% META $631.74 ▼-1.69% SPCX $145.06 ▼-1.64% NVDA $214.85 ▲+1.84% AAPL $343.74 ▼-1.14% SNDK $1,243.10 ▲+0.41% INTC $87.15 ▲+0.22%
FinancialContent

Immunocore Holdings plc - American Depositary Shares (NQ:IMCR)

31.46 +0.48 (+1.57%)
Delayed Quote Updated: 10:05 AM EDT, Oct 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immunocore Holdings plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Immunocore announces transition of Chief Financial Officer
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
The Latest Analyst Ratings For Immunocore Hldgs ↗
 
Via Benzinga
News headline image
Deep Dive Into Immunocore Hldgs Stock: Analyst Perspectives (9 Ratings) ↗
 
Via Benzinga
News headline image
Immunocore reports second quarter financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
3 Small-Cap Stocks with Significant Growth Potential ↗
As sector rotation continues, it could be time for investors to consider these small-cap growth stocks that institutions love. 
Via InvestorPlace
News headline image
Peeling Back The Layers: Exploring Immunocore Hldgs Through Analyst Insights ↗
 
Via Benzinga
News headline image
Analyst Expectations For Immunocore Hldgs's Future ↗
 
Via Benzinga
News headline image
Where Immunocore Hldgs Stands With Analysts ↗
 
Via Benzinga
News headline image
Immunocore to report second quarter 2024 financial results and host call on August 8, 2024
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore Hldgs Stock: A Deep Dive Into Analyst Perspectives (8 Ratings) ↗
 
Via Benzinga
News headline image
Key Takeaways From Immunocore Hldgs Analyst Ratings ↗
 
Via Benzinga
News headline image
Immunocore Hldgs's Earnings: A Preview ↗
 
Via Benzinga
News headline image
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore to present at the Jefferies Global Healthcare Conference
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
 
Via Benzinga
News headline image
IMCR Stock Earnings: Immunocore Hldgs Misses EPS, Misses Revenue for Q1 2024 ↗
IMCR stock results show that Immunocore Hldgs missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Immunocore reports first quarter financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore announces upcoming presentation and posters at ASCO 2024
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore to present at upcoming investor conferences
From Immunocore Holdings Limited
Via GlobeNewswire
News headline image
Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio ↗
One of the primary features of Bill Gates biotech stocks is they are all working towards a cure for HIV and related illnesses. 
Via InvestorPlace
News headline image
Immunocore presented two posters at CROI 2024
From Immunocore Holdings Limited
Via GlobeNewswire
News headline image
Immunocore to present at upcoming investor conferences
From Immunocore Holdings Limited
Via GlobeNewswire
News headline image
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
From Immunocore Holdings Limited
Via GlobeNewswire
News headline image
Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
From Immunocore Holdings Limited
Via GlobeNewswire
News headline image
Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024
From Immunocore Holdings Limited
Via GlobeNewswire
News headline image
Immunocore Prices Upsized Convertible Senior Notes Offering
From Immunocore Holdings Limited
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >